Articles published by Rubedo Life Sciences, Inc.

Rubedo Life Sciences Announces Clinical Study to Treat Hair Loss with GPX4 Modulator RLS-1496, First Human Ex Vivo Evidence Demonstrates Robust Hair Follicle Growth

September 16, 2026

From Rubedo Life Sciences, Inc.

Via Business Wire

Rubedo’s RLS-1496 Reduces Actinic Keratosis Pre-Cancerous Skin Lesions by 46% at Four Weeks with Minimal Irritation in Preliminary Results of Phase 1b/2a Study

May 28, 2026

From Rubedo Life Sciences, Inc.

Via Business Wire

Rubedo Life Sciences Announces Positive Preliminary Phase 1 Clinical Trial Results for Lead Drug Candidate RLS-1496 in Patients with Plaque Psoriasis, Atopic Dermatitis, and Skin Aging

March 26, 2026

From Rubedo Life Sciences, Inc.

Via Business Wire

Rubedo Life Sciences and SVAX Announce Strategic Partnership During FII Week in Riyadh

October 30, 2025

From Rubedo Life Sciences, Inc.

Via Business Wire

Rubedo Life Sciences Announces U.S. FDA Clearance of IND for Selective GPX4 Modulating Lead Drug Candidate RLS-1496 for Actinic Keratosis, Expands Clinical Advisory Board

September 17, 2025

From Rubedo Life Sciences, Inc.

Via Business Wire

Rubedo Life Sciences Announces First Patient Dosed with Lead Drug Candidate RLS-1496, the First GPX4 Modulator Targeting Pathologic Senescent Cells To Enter Phase 1 Clinical Trial

May 22, 2025

From Rubedo Life Sciences, Inc.

Via Business Wire

Rubedo Life Sciences’ Drug Discovery Platform, ALEMBIC™, Helps Identify Senescent or “Zombie” Neurons in New Study Linking Neuropathic Pain and Aging Published in Peer-Reviewed Scientific Journal Nature Neuroscience

May 14, 2025

From Rubedo Life Sciences, Inc.

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.